Cetrorelix CAS:120287-85-6
Cetrorelix is employed as a medication in the field of assisted reproductive technology, particularly in the context of in vitro fertilization (IVF). It is utilized to prevent premature ovulation in women undergoing controlled ovarian stimulation as part of an IVF treatment cycle. Premature ovulation can potentially interfere with the timing of egg retrieval, impacting the success of the fertilization process. As a gonadotropin-releasing hormone (GnRH) antagonist, cetrorelix works by competitively binding to GnRH receptors in the pituitary gland, thereby blocking the action of GnRH and subsequently inhibiting the release of luteinizing hormone (LH). This mechanism of action effectively prevents premature LH surges, which can trigger ovulation before the eggs are ready for retrieval. Cetrorelix is typically initiated during the ovarian stimulation phase of the IVF cycle and continues until the eggs reach the desired stage of maturation. Its use is carefully timed and coordinated with other medications utilized in IVF protocols to optimize the chances of successful oocyte retrieval and subsequent fertilization. Monitoring of hormone levels and ultrasound assessments guide the precise timing of cetrorelix administration to ensure effective control over the ovarian stimulation process. By preventing premature ovulation, cetrorelix supports the development and maturation of multiple follicles, allowing for the retrieval of a greater number of viable eggs for fertilization. The medication's role in maintaining control over the timing of ovulation induction contributes significantly to the success rates of IVF procedures, ultimately enhancing the prospects of achieving successful pregnancies for individuals undergoing fertility treatment. In summary, cetrorelix plays a crucial role in assisted reproductive technology, providing a means to prevent premature ovulation and supporting the optimal timing of egg retrieval during the course of IVF treatment. Its ability to effectively regulate the ovarian stimulation process contributes to the overall success of IVF procedures, offering hope and opportunities for individuals and couples pursuing fertility treatment to realize their dreams of starting or expanding their families.
Composition | C70H92ClN17O14 |
Assay | 99% |
Appearance | white powder |
CAS No. | 120287-85-6 |
Packing | Small and bulk |
Shelf Life | 2 years |
Storage | Store in cool and dry area |
Certification | ISO. |